[Current Status and Prospect of T790M Mutation in Non-small Cell Lung Cancer]

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are standard first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC).
• While first- and second-generation EGFR-TKIs improve progression-free survival (PFS), acquired resistance, frequently mediated by the T790M mutation (over 50% of cases), limits long-term efficacy.
• National Comprehensive Cancer Network (NCCN) guidelines now recommend third-generation EGFR-TKIs, such as Osimertinib, for first-line therapy in patients with detectable T790M mutations.

Purpose of the Study:

• To review the current landscape of EGFR-TKI therapy in NSCLC, focusing on the challenges posed by acquired resistance.
• To discuss the role and advancements in detecting and dynamically monitoring the T790M mutation.
• To explore the mechanisms of drug resistance to third-generation EGFR-TKIs and subsequent treatment strategies.

Main Methods:

• Literature review of studies on EGFR-TKIs in NSCLC.
• Analysis of clinical trial data regarding efficacy and resistance patterns.
• Discussion of emerging research on resistance mechanisms and monitoring techniques.

Main Results:

• Third-generation EGFR-TKIs demonstrate significant efficacy, with median PFS up to 13 months in some studies.
• The T790M mutation is a critical determinant of acquired resistance to earlier generation EGFR-TKIs.
• Challenges remain in the detection, dynamic monitoring, and management of resistance to third-generation EGFR-TKIs.

Conclusions:

• Sequential EGFR-TKI therapy, including third-generation agents, represents a significant advancement in NSCLC treatment.
• Further research is crucial to overcome resistance mechanisms and optimize treatment strategies for EGFR-mutated NSCLC.
• Effective T790M mutation detection and monitoring are essential for guiding treatment decisions and improving patient outcomes.